

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SANDOZ INC.,

Petitioner

v.

ELI LILLY AND COMPANY,

Patent Owner

U.S. Patent 7,772,209

Issue Date: Aug. 10, 2010

Title: Antifolate Combination Therapies

Inter Partes Review No. Unassigned

Declaration of Ron D. Schiff, M.D., Ph.D.

I.	BACKGROUND	4
II.	QUALIFICATIONS AND EXPERIENCE.....	4
III.	MATERIALS CONSIDERED	5
IV.	SUMMARY OF OPINIONS	5
V.	LEGAL PRINCIPLES.....	5
VI.	THE '209 PATENT	6
	A. Person of Ordinary Skill.....	6
	B. Overview	6
	C. Meaning of Claim Terms	7
	D. State of the Art	13
	E. Pemetrexed	17
VII.	ANALYSIS OF THE '209 PATENT	19
	A. It Would Have Been Apparent Prior To June 1999 To Pretreat Patients with Folic Acid And Vitamin B ₁₂ Before Administering Pemetrexed.....	19
	1. Folic Acid Pretreatment Was Known	19
	a. Folic Acid Pretreatment Was Known To Ameliorate Antifolate Toxicity	19
	b. Studies Recommended Folic Acid Pretreatment With Pemetrexed To Reduce Toxicity.....	26
	2. The Literature Suggested That Patients Should Also Be Pretreated With Vitamin B ₁₂	32
	B. The Specific Dosage Amounts And Schedules Required By The Claims Were Known	45
	1. 500 µg Dosages Of Folic Acid Were Standard Prior To June 1999.....	45
	2. Vitamin B ₁₂ Was Commonly Administered Via Repeated Intramuscular Injection in 1000 µg Doses	48
	a. Vitamin B ₁₂ Was Routinely Administered Parenterally in 1000 µg Doses.....	48

b.	It Was Known That Vitamin B12 Injections Should Be Repeated “About Every 6 to About Every 12 Weeks”	51
3.	Folic Acid Pretreatment From 1-3 Weeks And 1- 24 Hours Before Pemetrexed Therapy Was Known.....	52
C.	Administration of Cisplatin with Pemetrexed was Known.....	53
VIII.	CONCLUSION.....	54

I. BACKGROUND

1. My name is Ron D. Schiff. I hold M.D. and Ph.D. degrees from Saint Louis University, and am currently the principal of Schiff BioMedical Consulting.

2. I have been retained by counsel for Petitioner, Sandoz Inc. (“Sandoz”), to investigate and opine as to the validity of claims 1-22 of U.S. Patent No. 7,772,209 (“the ’209 patent”).

3. I am being compensated at my usual hourly rate for the time I spend working on this matter. My compensation is not contingent upon the substance of my testimony or the outcome of this matter.

II. QUALIFICATIONS AND EXPERIENCE

4. My qualifications and experience are set forth in my curriculum vitae, which is attached as Appendix A.

5. I worked as practicing physician in the field of oncology for 29 years with a specialty in internal medicine and sub-specialties in medical oncology and hematology.

6. I frequently treated patients with antifolates, particularly methotrexate which is used in the treatment of multiple hematologic and solid-organ malignancies, including acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, head and neck cancer, breast cancer, bladder cancer, and meningeal leukemia or lymphoma.

7. I have treated hundreds of patients with methotrexate throughout my 29 years of practice and since I began my post-graduate training in 1980. I have also administered pemetrexed and am familiar with its vitamin pre-treatment regimen.

III. MATERIALS CONSIDERED

8. In forming my opinions, I have reviewed, *inter alia*, the '209 patent and its prosecution history, as well as the exhibits referenced in Sandoz's Petition for *Inter Partes* Review. I understand that the exhibit numbers referenced in this declaration correspond to the same exhibit numbers used in Sandoz's petition. A copy of the exhibit list from Sandoz's petition is attached as Appendix B.

9. A list of the documents I have considered in preparing this declaration is attached as Appendix C.

10. This declaration is based upon information currently available to me. To the extent additional information becomes available, I reserve the right to continue my investigation and study.

IV. SUMMARY OF OPINIONS

11. For the reasons explained herein, claims 1-22 would have been obvious to the person of ordinary skill in the art as of June 1999.

V. LEGAL PRINCIPLES

12. I am a medical, not a legal, expert. Counsel for Sandoz has advised

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.